Compare Inovio Pharmaceuticals Inc (INO) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Li Auto Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Li Auto Inc trades at $12.28 (market cap $12.43B). The key difference: Li Auto Inc is far larger — about 139.2× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | LI | |
|---|---|---|
Market Cap | $89.27M | $12.43B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $30.84 |
52-Week Low | $1.05 | $11.74 |
Enterprise Value | $60.28M | $1.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
LI Auto trades at $12.42, up 0.24% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31B from $144.5B in 2024. Recent news highlights the launch of new SUV models like the Li L6, aiming to boost deliveries amid competitive pressures.
Outlook remains cautious with analyst consensus at Buy (43.75%) but near-term risks from intense EV competition and profitability challenges. The stock trades below the consensus price target of $14.80, offering potential upside if execution improves, but investors face headwinds from margin pressure and volatile cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
